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Abstract
IMPORTANCE—Abdominal pain after cholecystectomy is common and may be attributed to 
sphincter of Oddi dysfunction. Management often involves endoscopic retrograde 
cholangiopancreatography (ERCP) with manometry and sphincterotomy.
OBJECTIVE—To determine whether endoscopic sphincterotomy reduces pain and whether 
sphincter manometric pressure is predictive of pain relief.
DESIGN, SETTING, AND PATIENTS—Multicenter, sham-controlled, randomized trial 
involving 214 patients with pain after cholecystectomy without significant abnormalities on 
imaging or laboratory studies, and no prior sphincter treatment or pancreatitis randomly assigned 
(August 6, 2008-March 23, 2012) to undergo sphincterotomy or sham therapy at 7 referral medical 
centers. One-year follow-up was blinded. The final follow-up visit was March 21, 2013.
INTERVENTIONS—After ERCP, patients were randomized 2:1 to sphincterotomy (n = 141) or 
sham (n = 73) irrespective of manometry findings. Those randomized to sphincterotomy with 
elevated pancreatic sphincter pressures were randomized again (1:1) to biliary or to both biliary 
and pancreatic sphincterotomies. Seventy-two were entered into an observational study with 
conventional ERCP managemeny.
MAIN OUTCOMES AND MEASURES—Success of treatment was defined as less than 6 days 
of disability due to pain in the prior 90 days both at months 9 and 12 after randomization, with no 
narcotic use and no further sphincter intervention.
RESULTS—Twenty-seven patients (37%; 95%CI, 25.9%-48.1%) in the sham treatment group vs 
32 (23%; 95%CI, 15.8%-29.6%) in the sphincterotomy group experienced successful treatment 
(adjusted risk difference, −15.6%; 95% CI, −28.0% to −3.3%; P = .01). Of the patients with 
pancreatic sphincter hypertension, 14 (30%; 95% CI, 16.7%-42.9%) who underwent dual 
sphincterotomy and 10 (20%; 95% CI, 8.7%-30.5%) who underwent biliary sphincterotomy alone 
experienced successful treatment. Thirty-seven treated patients (26%; 95% CI,19%-34%) and 25 
patients (34%; 95% CI, 23%-45%) in the sham group underwent repeat ERCP interventions (P = .
22). Manometry results were not associated with the outcome. No clinical subgroups appeared to 
benefit from sphincterotomy more than others. Pancreatitis occurred in 15 patients (11%) after 
primary sphincterotomies and in 11 patients (15%) in the sham group. Of the nonrandomized 
patients in the observational study group, 5 (24%; 95%CI, 6%-42%) who underwent biliary 
sphincterotomy, 12 (31%; 95%CI, 16%-45%) who underwent dual sphincterotomy, and 2 (17%; 
95%CI, 0%-38%) who did not undergo sphincterotomy had successful treatment.
CONCLUSIONS AND RELEVANCE—In patients with abdominal pain after cholecystectomy 
undergoing ERCP with manometry, sphincterotomy vs sham did not reduce disability due to pain. 
These findings do not support ERCP and sphincterotomy for these patients.
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TRIAL REGISTRATION—clinicaltrials.gov Identifier: 00688662
Postcholecystectomy pain is a common clinical problem. More than 700 000 patients 
undergo cholecystectomy each year in the United States,1 and at least 10% are reported to 
have pain afterwards.2 A few are found by standard investigations to have a biliary cause 
(eg, duct stone) and some are diagnosed with other abdominal pathology or functional bowel 
disease.3 Most have no significant abnormalities on imaging or laboratory testing, and the 
cause remains obscure. Many of these patients undergo endoscopic retrograde 
cholangiopancreatography (ERCP) in the hope of finding small stones or other pathology or 
in an effort to address suspected sphincter of Oddi dysfunction.4 Of these patients, some 
undergo biliary or pancreatic sphincterotomy or both. The value of this endoscopic 
intervention is unproven and the risks are substantial. Procedure-related pancreatitis rates are 
10% to 15%,5 and perforations may occur. Many patients have prolonged and expensive 
hospital stays, and some die.6
Sphincter of Oddi dysfunction has been divided into 3 types.3 Type I consists of patients 
with a dilated bile duct and abnormal liver tests, type II involves one of those criteria but not 
both, and type III have none of those criteria. A National Institutes of Health conference in 
2002 raised concerns about the safety of ERCP in this context. It recommended that patients 
with suspected sphincter of Oddi dysfunction types II and III be referred to tertiary centers 
able to perform sphincter manometry.7 However, sphincter manometry has never been 
shown to predict the outcome of sphincterotomy in patients with sphincter of Oddi 
dysfunction type III, and cohort studies have shown unimpressive results.8-10 There has been 
only a single sham-controlled study that was reported in abstract form only, showing that 8 
of 13 patients treated by biliary sphincterotomy improved compared with 3 of 10 control 
patients.11 Placebo effects are likely strong; the pain response rates in the sham groups of 
the published trials in patients with sphincter of Oddi dysfunction type II were 33% and 
42%.12,13
Thus, the current practice of performing ERCP in these patients, with or without 
sphincterotomy, and with or without manometry, is not supported by evidence. In addition 
to the significant risks of the procedure, many patients who do not benefit undergo more 
ERCPs and even surgical interventions. Several authors have expressed concerns about this 
practice.8-10,14,15
We performed a multicenter study to determine the effectiveness and safety of endoscopic 




The Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD) 
trial is a sham-controlled, randomized, double-blind clinical trial. Details of the design have 
been published.16 The study protocol was approved by the institutional review board at each 
site, and all patients gave written informed consent.
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Patients in 7 US centers were considered for the study if they were aged 18 to 65 years, had 
pain more than 3 months after cholecystectomy, no history of pancreatitis (or evidence for it 
on imaging and laboratory tests), and no prior sphincter intervention. Patients fulfilling these 
criteria were considered further if treatment with acid-suppressing agents and 
antispasmodics failed, had normal upper endoscopy and abdominal imaging (with a bile duct 
diameter of ≤9 mm), and if taking antidepressants were maintaining a stable dose of 
medications. They were excluded if within the last 6 months levels of direct bilirubin, 
alkaline phosphatase, amylase, or lipase were more than twice normal or if transaminases 
were more than 3 times normal; if narcotic analgesics were used every day in the past 
month; if they were known to have pancreas divisum, prior surgical biliary diversion, 
abnormal endoscopic ultrasound (if done), significant psychiatric or other major medical 
problems; or, were pregnant.
The proposed randomized study was explained to patients fulfilling the initial criteria. Those 
consenting completed a battery of questionnaires, including demographics, pain burden, 
details of the cholecystectomy and its effect on pain, psychological disorders as measured by 
the Mini International Neuropsychiatric Interview (MINI)17; Beck Depression Inventory 
(BDI-II)18; Hospital Anxiety and Depression Scale (HADS)19; Trauma Questionnaire-Short 
Form20; Coping Questionnaire-Catastrophizing Subscale21; Rome III Functional 
Gastrointestinal Disorders Diagnostic Module,22 including the Biliary Disorders module, 
which was modified to allow daily pain (≤2 on a 0-10 scale) as well as intermittent episodes; 
36-Item Short Form Health Survey (36-SH) for quality of life23; and economic resource use. 
The patient’s pain disability was assessed using the Recurrent Abdominal Pain Intensity and 
Disability (RAPID) instrument, which was developed and validated specifically for this 
study24 The RAPID score is the patient’s recall of how much productivity in 3 domains 
(paid work or school, household activities, and nonwork activities) was lost in the prior 90 
days due to abdominal pain episodes. Thus, the score ranges from 0 to 270. The RAPID 
score has 4 grades: grade 1 indicates 6 days or less; grade 2, 6 to 10 days; grade 3, 11 to 20 
days; and grade 4, 20 days or more.24
Patients were excluded from the study if they reported major psychiatric disorders 
(psychotic or bipolar disorder), severe depression (BDI score, ≥22), suicidal risk, 
insufficient pain disability (RAPID score, <11 days of disability in the past 3 months), or 
pain characteristics not consistent with the modified Rome III definition. Two of the entry 
criteria were revised early in the study. The pain criterion was changed to allow daily 
discomfort as well as pain episodes (modifying the Rome III criteria). In addition, the 
acceptable limit for transaminases of twice normal was raised to 3 times normal. These 
changes occurred when only 10 patients had been randomized, with approval of the data 
safety and monitoring board.
Patients who met all of the above criteria but declined randomization were offered 
enrollment into an observational study, EPISOD 2. They were studied and followed up in 
the same manner as patients randomized to the EPISOD trial, except that biliary, pancreatic 
sphincterotomies, or both were performed based on manometry results, as is commonly 
practiced, and the patients were not blinded.
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Eligible patients underwent ERCP by very experienced endoscopists, under conscious 
sedation, modified or full anesthesia, based on local practice. Sphincter of Oddi manometry 
was performed by the standard water-perfusion method, using a basal pressure of more than 
40 mm Hg in both leads to define abnormality in the biliary and pancreatic sphincters. Using 
a centralized web-based system, patients with successful pancreatic manometry and not 
having duct abnormalities, such as pancreas divisum, were then randomized with a 2:1 
allocation to sphincterotomy or sham. The randomization algorithm was a permuted block 
scheme with random block size stratified by clinical center and the presence or absence of 
pancreatic sphincter hypertension. Because experts in tertiary centers will sometimes treat 
patients with biliary-type pain and pancreatic sphincter hypertension with pancreatic 
sphincterotomy, a secondary aim was to compare the results of dual (biliary and pancreatic) 
sphincterotomy with those of biliary sphincterotomy alone. Thus, patients allocated to 
sphincterotomy who had pancreatic sphincter hypertension were randomized a second time 
using a 1:1 ratio to either biliary or dual sphincterotomy.
All patients (including those in the sham group with no sphincterotomy) received small-
caliber (3-5 Fr diameter) pancreatic stents to reduce the risk of postprocedure pancreatitis; 
these pass spontaneously within 1 to 4 weeks. Antiinflammatory medications now known to 
reduce postprocedure pancreatitis were not given. Patients were blinded to treatment 
allocation, observed in the hospital overnight, and returned to their blinded referring 
physicians for clinical follow-up. Blinded research coordinators at each site called the 
patients 1 week after undergoing the procedure and monthly for 12 months. In addition, calls 
were made at 9 and 12 months by blinded research staff at the central coordinating center to 
collect primary outcome information. Patients with persistent burdensome pain either 
consulted their referring physicians, who decided on treatment blinded to the original 
treatment allocation, or returned to the study site and were seen by an evaluating physician, 
also blinded to the treatment allocation. By definition, treatment was considered failed if a 
patient had undergone a second ERCP intervention or if the patient was recommended by 
the evaluating physician to undergo a second intervention, even if the treating physician 
disagreed.
Study Outcomes
The primary outcome was a dichotomous (success/failure) variable. Treatment success was 
defined as patients having a RAPID score of fewer than 6 days of lost productivity at 
months 9 and 12 after the endoscopic procedure, did not undergo a second intervention, and 
did not require narcotics during months 10, 11, and 12 unless they needed it for other than 
abdominal pain for no more than 14 days. If the 12-month RAPID score was missing or 
collected outside the acceptable window (within 6 months of the expected 12-month visit), 
the treatment was considered to have failed the patient for the primary outcome. If the 9-
month RAPID score was missing or was outside of the window (within 3 months of the 
expected 9-month visit), then the 6-month value was used instead when available.
Secondary outcomes included association of manometry results and prespecified potential 
prognostic clinical factors (age, time since cholecystectomy, whether stones were present, 
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whether there was a period of pain relief after surgery, presence of daily discomfort, 
elevated liver enzymes, other concomitant functional digestive disorders, narcotic use, and 
psychiatric status) with the primary outcome, the outcome of patients receiving biliary 
sphincterotomy compared with dual sphincterotomy, quality of life, and resource utilization. 
Adverse events were collected throughout the study period and were monitored by an 
independent medical safety monitor, and a data and safety monitoring board.
Statistical Analysis
The trial was designed to test for an overall absolute difference of at least 30%in the primary 
outcome in patients treated with sphincterotomy (dual or biliary) compared with those 
treated with sham. The sham success rate was expected to be 30%.8,9,12,13 The choice of an 
absolute difference between treatment groups of 30%was based on published data7-9 and 
pilot studies conducted during the planning stages of this study.
Based on this information and the 2:1 allocation, an assumed 10% nonadherence rate, and 1 
interim analysis for efficacy using O’Brien and Fleming boundaries25 and futility using 
conditional power, the study required 214 patients to be randomized to ensure greater than 
90% likelihood of identifying this difference.
The primary analysis was conducted using a logistic regression model with the treatment 
group as the factor of interest and clinical center and pancreatic sphincter hypertension 
status as covariates. An unadjusted analysis of the primary outcome was conducted as a 
sensitivity analysis. A Wald test was used to compare the treatment group proportions using 
a 2-tailed significance level of .05. Adjusted and unadjusted risk differences with 2-sided 
95% confidence intervals are reported. All analyses were conducted with the intention-to-
treat population defined as all randomized patients. A sensitivity analysis was conducted 
with the completer population defined as all randomized patients who did not have a missing 
or late RAPID score at months 9 and 12.
Results
Patients and Baseline Characteristics
A total of 1584 fitting the 4 basic criteria (postcholecyctectomy pain, aged 18-65 years, no 
pancreatitis and no prior sphincter intervention) patients underwent preliminary screening 
prior to consent. Of these, 1112 (70%) were excluded. Many patients met more than 1 of the 
exclusion criteria. The following are the most common: 215 had abnormal findings on 
abdominal imaging or upper endoscopy; 206, atypical or little pain; 158, daily use of 
narcotics; and 224, liver or pancreas laboratory screening results higher than allowed limits. 
In addition, 74 patients (5%) declined consent. Three hundred ninety-eight patients 
consented and completed study questionnaires. Of those, 88 did not meet the specific 
criteria. The most common reasons were that 32 patients had established psychiatric 
disorders and 28 did not have biliary pain by modified Rome III criteria. One patient 
withdrew consent. Of the remaining 309 potential candidates, 72 declined randomization but 
consented to be enrolled into the observational study. Two hundred thirty-seven patients 
underwent ERCP. Twenty-three of those patients were excluded: 17 had pancreas divisum, 2 
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did not have clinically relevant pathology, 3 had unsuccessful manometry, and 1 could not 
be adequately sedated (Figure 1).
Of the 214 patients who were randomized, 73 were assigned to the sham group and 141 to 
sphincterotomy group. Patients were randomized between August 6, 2008, and March 23, 
2012. The last follow-up occurred on March 21, 2013. The 2 treatment groups were well 
balanced with respect to baseline demographic and clinical characteristics (Table 1), as 
described elsewhere.26 Pancreatic sphincter manometry was abnormal (with or without 
biliary abnormality) in 64% of the patients; biliary manometry alone was abnormal in 12%. 
As reported elsewhere, abnormal sphincteric pressures were not influenced by the type of 
sedation or anesthesia and did not correlate with the patient’s clinical characteristics.27
Primary Outcome
Most patients in both study groups showed considerable reductions in their RAPID score by 
3 months (Figure 2). The interim analysis was conducted after one-third, 72 patients, 
completed the 12-month follow-up. At that time, the P value of a χ2 test was .03, failing to 
reach the stopping boundary for overwhelming efficacy. The conditional power under the 
alternative hypothesis was 64% and 2% under the null hypothesis. Based on this 
information, the data and safety monitoring board recommended continuation of the trial. 
The rate of successful outcome as defined at 12 months was 37% for the 73 patients 
assigned to sham, and 23% for the 141 assigned to sphincterotomy (adjusted risk difference, 
−15.6%; 95% CI, −28.0% to −3.3%; P = .01; Table 2). A total of 23 patients had missing or 
late RAPID scores and no record of narcotic use or reintervention): 15 (11%) in the 
sphincterotomy group and 8 (11%) in the sham group. The primary outcome was imputed 
for these cases according to the study missing data plan described above.
The most common reason for failure in both treatment groups (72% sphincterotomy, 56% 
sham) was persistent elevation in the RAPID pain-disability score, with or without 
reintervention or narcotic use (eTable in the Supplement). A secondary sensitivity analysis 
of the primary outcome of the 173 patients that had complete outcome data revealed similar 
results. The success rate for the completer population in the sham group was 42% and in the 
sphincterotomy group, it was 25% (adjusted risk difference, −18.6%; 95% CI, −33.0% to 
4.3%).
Safety Outcomes
The ERCP procedures at randomization caused pancreatitis in 26 patients, 11% in the 
sphincterotomy group and 15% in the sham group (unadjusted relative risk, 0.71; 95% CI, 
0.34-1.46). Two of the events were defined as severe (1 in the biliary sphincterotomy group, 
1 in sham group), 10 moderate, and 14 mild, using standard consensus criteria.28 One patient 
in the dual group experienced retroduodenal perforation after sphincterotomy, which 
required surgical treatment. Another, in the sham group, had evidence for microperforation 
in association with pancreatitis. There were no procedure-related episodes of bleeding or 
infection and no deaths.
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Ten patients 20% (95% CI, 8.7%-30.5%) with pancreatic sphincter hypertension assigned to 
the biliary sphincterotomy group and 14 patients 30% (95% CI, 16.7%-42.9%) assigned to 
dual biliary and pancreatic sphincterotomy experienced successful treatment (Table 2).
None of the prespecified clinical factors predicted success; these included age, reason for 
cholecystectomy and response to it, pain characteristics, and psychosocial comorbidities. In 
particular, there was no difference in outcomes between patients with and without daily 
abdominal discomfort or between those with and without any minor liver test abnormalities.
To examine whether our definition of treatment success was robust, we considered other 
post hoc criteria. Although the success rates were higher when we substituted a 50% 
reduction in the RAPID score (still counting reinterventions and narcotic use as failures), 
there was no difference between groups: sham success, 47% (95%CI, 35.1%-58.0%); 
sphincterotomy, 38% (95% CI, 29.6%-45.6%). Similar results were found when the narcotic 
criteria were removed: sham success, 38% (95% CI, 27.2%-49.5%); sphincterotomy, 27% 
(95% CI, 19.6%-34.3%). The reintervention rate, when examined alone, was not 
significantly higher in the sham group (34%; 95% CI, 23%-45% vs 26%; 95% CI, 
19%-34%; P = .22). In a sensitivity analysis to assess the extreme effect of sphincterotomy, 
we considered treatment to be successful among all the patients with missing or late follow-
up data vs considering treatment failure among patients in the sham group whose data were 
missing or late and found that the treatment success rate for the sphincterotomy group was 
31.2% (95% CI, 23.6%-38.9%) vs 31.5% (95% CI, 20.8%-42.2%) for the sham group. The 
adjusted risk difference was −4.8%, (95% CI, −17.0% to 7.4%; P = .44, adjusted for 
pancreatic sphincter hypertension and study site).
The 12-month SF-36 composite scores for physical and mental health and the HADS anxiety 
and depression scores improved from baseline; however, the change scores did not differ 
between the 2 treatment groups (Table 3).
The association between the results of manometry and primary outcome in those 
randomized to sphincterotomy was examined. The presence of pancreatic sphincter 
hypertension (regardless of biliary hypertension) was not associated with the primary 
outcome (P = .70). In addition, patients with pancreatic or biliary hypertension did not have 
a higher success rate than those without sphincter hypertension (P = .55; Table 4). We 
similarly found no association with the primary outcome when we explored higher 
manometric pressure cut points.
In the observational study of patients who were not randomized, the use of sphincterotomy 
was guided by the results of manometry, as is usually done in clinical practice. The baseline 
demographic and clinical characteristics of the 72 patients were similar to the randomized 
population.26 The success rates for these unblinded patients, using the same criteria as in 
EPISOD, were also similar: 24% (n = 5; 95%CI, 6%-42%) for biliary sphincterotomy, 31% 
(n = 12; 95% CI, 16%-45%) for dual sphincterotomy, and 17% (n = 2; 95% CI, 0%-38%) 
for those with normal manometry and no sphincterotomy.
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We report the results of a randomized, sham-controlled trial of sphincterotomy involving 
patients with pain after cholecystectomy and without significant liver test abnormalities or a 
dilated bile duct. Although many patients had a considerable reduction in their disability due 
to pain, we found that sphincterotomy was not more effective than a sham endoscopic 
procedure and that manometric pressure findings were not associated with the 
sphincterotomy outcome. Furthermore, we did not find any clinical characteristics that were 
associated with success, including factors proposed previously, such as age, pancreatic 
manometric pressures,29 and pain patterns.30 We confirmed that ERCP carries substantial 
risks, even in expert hands.
The finding that endoscopic sphincterotomy is not an effective treatment has major 
implications for clinical practice because it applies to many thousands of patients. Several 
series have reported residual or recurrent pain in more than 20% of patients after elective 
cholecystectomy.2,31-34 The number of cholecystectomies has increased recently, especially 
for suspected gallbladder dyskinesia.35 Furthermore, the US Householders Survey36 found 
that 1.5% of the adult population reported symptoms consistent with sphincter of Oddi 
dysfunction.
Our conclusions apply to patients with sphincter of Oddi dysfunction type III characteristics. 
It is noteworthy that we observed no benefit for sphincterotomy in the small number of our 
patients who did have some liver test abnormalities (ie, type II). Application of manometry-
directed biliary sphincterotomy in type II patients is based on limited data,11,12 and further 
study of type II patients may be justified.
Several potential study limitations need to be considered. First, the primary outcome 
measure might be considered to be too restrictive. The study was designed intentionally to 
have a stringent primary outcome in view of the known risks of ERCP and sphincterotomy. 
However, the conclusion remained robust in post hoc analyses using less stringent 
diagnostic criteria. Other sphincterotomy studies showing favorable outcomes used 
subjective and not objective measures of success7,8 or defined success only as the lack of 
further intervention.37 A second potential criticism, that patients who consent to a 
randomized sham-controlled trial might not be representative of most patients with the 
condition, was addressed by examination of the patients who declined to be randomized and 
were enrolled in the observational study. These patient’s basal characteristics and outcomes 
were similar to the patients who were randomized. Another potential limitation was that our 
protocol deviated slightly from the strict Rome III definition of biliary pain3 by allowing 
enrollment of patients with some daily discomfort in addition to episodes of pain. However, 
the results were no different in the patients with daily discomfort, nor was it different in 
those who had some minor laboratory abnormalities. Lastly, patients in the sham group 
underwent ERCP cannulation, manometry, and temporary stenting. It could be argued that 
these procedures were themselves somehow therapeutic, but it is highly unlikely that any 
such effect would last for a year. We did not include a second no-touch sham group because 
that would have increased complexity and cost and may have adversely affected recruitment.
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We speculate that the early reduction in pain-related disability in all groups may be related 
to a placebo response in a cohort of optimistic and distressed patients who received support 
by continuing contact with our research staff. Other surgical and endoscopic randomized 
studies demonstrated similar success rates of about 30% in sham groups,38,39 with benefits 
persisting for years.40 A blinded cohort of the EPISOD and EPISOD 2 patients is being 
followed up for an additional 2 years to further assess this phenomenon. We have also 
considered the potential for regression to the mean to explain the large decrease in RAPID 
scores from baseline. Although that is possible, the reduction occurred equally in all study 
groups and does not affect the overall conclusions of the trial.
Conclusions
Among patients with abdominal pain after cholecystectomy (and with no significant 
laboratory or imaging abnormalities) undergoing ERCP with manometry, sphincterotomy 
compared with a sham procedure did not reduce disability due to pain. These findings do not 
support the use of ERCP and sphincterotomy for these patients.
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Figure 1. Flow Diagram Documenting Recruitment and Treatment Allocations
a Patients who were eligible for the study but who declined randomization were treated by 
conventional manometry-directed sphincterotomy. ERCP indicates endoscopic retrograde 
cholangiopancreatography; PPI, proton pump inhibitor.
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Figure 2. RAPID Score Distribution by Assigned Treatment Group and Visit
The boxes indicate interquartile ranges; circle within box, mean; horizontal line within box, 
median; error bars, 1.5 times the interquartile range; and circles, outliers. RAPID indicates 
Recurrent Abdominal Pain Intensity and Disability.
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Table 1
Baseline Characteristics of Study Population by Assigned Treatment Groupa
Demographics
No. (%) of Patients
Sphincterotomy (n = 141) Sham (n = 73)
Age, mean (SD) [range], y 38 (11) [19-64] 39 (11) [20-59]
Women 128 (91) 69 (95)
Race/ethnicity
 Black 5 (4) 3 (4)
 White 132 (94) 70 (96)
 Other race/unknown 4 (2) 0 (0)
Employment
 Full-time 81 (57) 43 (59)
 Part-time 20 (14) 12 (16)
 Homemaker 17 (12) 4 (5)
Elevated liver enzymesb 11 (8) 8 (11)
Gallstones at cholecystectomy 67 (48) 34 (47)
Pain relief after cholecystectomy 100 (71) 47 (64)
Daily abdominal discomfort in past 30 d 74 (52) 36 (49)
Abnormal sphincter manometry 110 (78) 52 (71)
 Pancreatic only 42 (30) 22 (30)
 Biliary only 16 (11) 9 (12)
 Pancreatic and biliary 52 (37) 21 (29)
Irritable bowel syndrome 45 (32) 28 (38)
DSM-IV depressive disorders (current)c 10 (7) 7 (10)
DSM-IV anxiety disorders (current)c 9 (6) 10 (14)
Physical/sexual abuse 38 (27) 13 (18)
Narcotics use (in last mo) 40 (28) 16 (22)
Antidepressant/anxiolytic use 55 (39) 29 (40)
Time from cholecystectomy to randomization, mean (SD) [range], y 4 (4.57) [0.27-21.08] 5 (6.67) [0.25-41.67]
Pain; Baseline RAPID score, mean (SD) [range]c 82 (52.76) [11-251] 89 (67.28) [11-270]
Days of pain episodes in past 90 d, mean (SD) [range] 69 (27.08) [0-90] 69 (26.10) [3-90]
Average pain intensity (0-10) in past 90 d, mean (SD) [range] 7 (1.83) [3-10] 7 (1.99) [3-10]
SF-36 Pain Scale, mean (SD) [range]d 35 (15.58) [0-84] 35 (18.26) [0-100]
HADS, mean (SD) [range]c
 Anxiety (0-21) 4 (3.56) [0-16] 5 (3.37) [0-13]
 Depression (0-21) 3 (3.12) [0-16] 4 (3.05) [0-11]
BDI-II (0-63), mean (SD) [range]c 7.5 (5.32) [0-23] 8 (5.54) [0-26]
CSQ-CAT score (0-36) (coping/catastrophizing), mean (SD) [range]c 7 (6.30) [0-32] 9 (7.26) [0-28]
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Demographics
No. (%) of Patients
Sphincterotomy (n = 141) Sham (n = 73)
SF-36, mean (SD) [range]d
 Physical 38 (8.19) [19.43-54.69] 40 (7.22) [20.31-56.58]
 Mental 49 (9.20) [17.86-66.89] 48 (10.36) [16.37-63.32]
Abbreviations: BDI, Beck Depression Inventory; CSQ-CAT, Coping Questionnaire Catastrophizing Subscale; DSM-IV, Diagnostic and Statistical 
Manual of Mental Disorders (Fourth Edition); HADS, Hospital Anxiety and Depression Scale; RAPID, Recurrent Abdominal Pain Intensity and 
Disability; SF-36, 36-Item Short Form Health Survey.
a
There was no significant difference between the 2 treatment groups.
b
Elevated transaminases of at least 3 × normal or alkaline phosphatase at least 2 × normal.
c
Higher scores mean worse health.
d
Higher score means better health.
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